Hone Health's $228 Million Round Is Mostly Not Equity. How General Catalyst's Customer Value Fund Works, and Which Founders It Fits
New York-based Hone Health announced $228 million in financing, but only $28 million is equity, a Series A extension led by MarcyPen Capital Partners. The other $200 million is growth financing from General Catalyst's Customer Value Fund, which pre-funds customer acquisition and is repaid from the revenue those customers bring in. How the structure works, what it costs founders and who qualifies.

NEW YORK — The headline number was $228 million. The more interesting number for founders is $28 million.
Hone Health, a physician-led longevity platform, announced the financing on Nov. 18 with a New York dateline. According to the company, the deal is structured as $28 million in equity, an extension of its Series A, plus $200 million in growth financing from General Catalyst’s Customer Value Fund (CVF). The equity brings Hone’s total equity funding to $65 million.
For any founder whose business runs on paid customer acquisition, the structure is worth understanding.
The Company
Saad Alam co-founded Hone in 2020 as an online clinic treating men with low testosterone, Fortune reported. It now offers biomarker testing, physician consultations and treatment spanning testosterone and menopause hormone therapy, weight management, thyroid, heart and sexual health. The company says it has treated more than 200,000 patients and administered 750,000 tests. Alam told Fortune that Hone broke through $100 million in recurring revenue last year. Tech Funding News reported that the company has about 450 staff and operates only in the U.S.
MarcyPen Capital Partners, whose co-founders include Shawn “Jay-Z” Carter and Jay Brown, led the equity. Hone disclosed that MarcyPen had also led its earlier Series A, a role it hadn’t previously made public. Pentland Ventures, Kinship Ventures, Hanwha, Gannet Capital, humbition, Comma Capital and ID Ventures also participated, along with a long list of entertainment and sports figures.
Hone says the money will fund new clinical programs, expanded diagnostics, AI clinical tools, a physician-supervised peptide program and clinical trials. Alam told Fortune most of the $28 million will go to AI. The company is also launching Hone Black, a concierge tier whose treatment options include exosome and stem cell therapies. Tech Funding News noted that the FDA has warned exosome products are unapproved.
How the Customer Value Fund Works
General Catalyst has described the model as treating sales and marketing spend as an asset. In its account:
- GC pre-funds a company’s sales and marketing budget. Axios reported in 2024 that it covers up to 80% of a company’s monthly sales and marketing spend.
- Repayment comes from the customers that spending acquires. GC is entitled to the customer value created by that spend, up to a fixed cap. After it reaches the cap, the rest of those customers’ lifetime value belongs to the company.
- GC takes the downside. If a period’s spending doesn’t produce customers, GC doesn’t get repaid for it. “The company never comes out of pocket to pay GC back,” the firm wrote.
Alam described it to Fortune in practical terms: he can call General Catalyst each month, ask for $10 million, spend it acquiring patients, then pay back a portion of the profit from those patients plus interest. He said there’s no recourse and no covenants restricting Hone from raising other money, and that “it’s actually shocking how small the interest rate is on it.” Hone didn’t disclose the actual terms.
The fund has been busy. Tech Funding News reported that CVF provided Function Health with $450 million in July, and TechCrunch reported that health drink startup IM8 took $1 billion from it the same month.
Why Founders Care: Dilution
GC’s argument is that using equity to pay for customer acquisition is expensive. Once a company has product-market fit, the firm wrote, the return on sales and marketing becomes fairly predictable, so it should be financed like a predictable asset, while equity is saved for riskier bets like product, engineering and new markets.
Hone is a clean example: it lined up $200 million for growth while selling only $28 million of stock.
Who Actually Qualifies
This isn’t seed-stage money. In 2024, Axios reported that companies in the program were typically fairly mature, spending $2 million to $20 million a month on sales and marketing and generating $30 million to $750 million in annual revenue. Alam said General Catalyst only offers the deal to companies whose patients stay at a steady rate.
Before pursuing this kind of capital, or any revenue-linked financing, founders should be able to answer:
- Do you know your payback period by cohort? Lenders will want customer acquisition cost, retention and revenue per customer tracked month by month, not just blended.
- Is retention steady? A structure repaid from customer revenue only works if customers stick around predictably.
- Is your spend repeatable? Financing assumes the next dollar of marketing performs like the last one.
- What does it really cost? Ask for the cap, the share of revenue, any fees and what happens if you raise equity or get acquired.
- What happens in a bad month? GC says it absorbs the downside of a weak cohort. Many other revenue-based products don’t, and Axios noted the non-dilutive financing sector has had bumps, including Clearco’s layoffs and recapitalization.
Earlier-stage New York founders have other non-dilutive options, including the kind of inventory and forward-flow financing we’ve covered before. But Hone’s deal shows where the market is heading: for companies with proven customer economics, the biggest check in the round may no longer be equity.
